A Phase 3 interventional study of Valsartan 0.25 mg/kg and Valsartan 1.0 mg/kg in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in 11 countries. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2011-05-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 107th largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 75th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 6 Months to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 175th largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2007, is one of 108 in phase 3, and was the 114th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of three doses of valsartan (0.25, 1.0, and 4.0 mg/kg) on mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) in 6 months - 5 year old children with hypertension (sitting systolic blood pressure [SSBP] ≥ 95th percentile ).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Valsartan 0.25 mg/kg
Drug: Valsartan 1.0 mg/kg
Drug: Valsartan 4.0 mg/kg
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6)
Time frame: baseline and week 6
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)to End of Period 1 (Week 6)
Time frame: baseline and week 6
Change From End of Period 1 (Week 6) in Mean Sitting Systolic Blood Pressure (MSSBP) to End of Placebo-controlled Withdrawal Period (Week 8)
Time frame: week 6 and week 8
Change From End of Period 1 (Week 6) in Mean Sitting Diastolic Blood Pressure (MSDBP) to End of Placebo-controlled Withdrawal Period (Week 8)
Time frame: week 6 and week 8
At period 1, participants were randomized (2:1:2) to Valsartan 0.25 mg/kg, 1.0 mg/kg or 4.0 mg/kg. At period 2, participants were randomized (1:1) to either stay on Valsartan or switch to placebo.
| Milestone | Low Dose in Both Periods | Low Dose, Then Placebo | Medium Dose in Both Periods | Medium Dose, Then Placebo | High Dose in Both Periods | High Dose, Then Placebo |
|---|---|---|---|---|---|---|
| Started | 15 | 15 | 6 | 8 | 15 | 15 |
| Completed | 15 | 15 | 6 | 8 | 15 | 15 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Low Dose in Both Periods | Low Dose, Then Placebo | Medium Dose in Both Periods | Medium Dose, Then Placebo | High Dose in Both Periods | High Dose, Then Placebo |
|---|---|---|---|---|---|---|
| Started | 15 | 15 | 6 | 8 | 15 | 15 |
| Completed | 15 | 14 | 6 | 8 | 15 | 15 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| mm Hg | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6) | -8.3 ± 10.44 | -10.3 ± 9.83 | -14.4 ± 10.93 |
| mm Hg | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)to End of Period 1 (Week 6) | -4.7 ± 9.53 | -8.6 ± 12.43 | -6.7 ± 10.61 |
| mm Hg | Valsartan | Placebo |
|---|---|---|
| Change From End of Period 1 (Week 6) in Mean Sitting Systolic Blood Pressure (MSSBP) to End of Placebo-controlled Withdrawal Period (Week 8) | 2.6 ± 8.38 | 4.1 ± 9.66 |
| mm Hg | Valsartan | Placebo |
|---|---|---|
| Change From End of Period 1 (Week 6) in Mean Sitting Diastolic Blood Pressure (MSDBP) to End of Placebo-controlled Withdrawal Period (Week 8) | 1.8 ± 8.99 | 3.4 ± 8.74 |
Collected over Period 1 (Baseline to Week 6) and Period 2 (Week 6 to Week 8). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose in Both Periods | — | 1/15 (6.7%) | 8/15 (53.3%) |
| Low Dose, Then Placebo | — | 0/15 (0%) | 10/15 (66.7%) |
| Medium Dose in Both Periods | — | 0/6 (0%) | 3/6 (50%) |
| Medium Dose, Then Placebo | — | 1/8 (12.5%) | 4/8 (50%) |
| High Dose in Both Periods | — | 0/15 (0%) | 9/15 (60%) |
| High Dose, Then Placebo | — | 2/15 (13.3%) | 11/15 (73.3%) |
| Event | Low Dose in Both Periods | Low Dose, Then Placebo | Medium Dose in Both Periods | Medium Dose, Then Placebo | High Dose in Both Periods | High Dose, Then Placebo |
|---|---|---|---|---|---|---|
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/15 | 0/15 | 0/6 | 1/8 | 0/15 | 0/15 |
| EnteritisGastrointestinal disorders | 0/15 | 0/15 | 0/6 | 0/8 | 0/15 | 1/15 |
| GastritisGastrointestinal disorders | 1/15 | 0/15 | 0/6 | 0/8 | 0/15 | 0/15 |
| Respiratory tract infectionInfections and infestations | 1/15 | 0/15 | 0/6 | 0/8 | 0/15 | 0/15 |
| Upper respiratory tract infectionInfections and infestations | 1/15 | 0/15 | 0/6 | 0/8 | 0/15 | 1/15 |
| DehydrationMetabolism and nutrition disorders | 0/15 | 0/15 | 0/6 | 0/8 | 0/15 | 1/15 |
| Nephrotic syndromeRenal and urinary disorders | 1/15 | 0/15 | 0/6 | 0/8 | 0/15 | 1/15 |
| Event | Low Dose in Both Periods | Low Dose, Then Placebo | Medium Dose in Both Periods | Medium Dose, Then Placebo | High Dose in Both Periods | High Dose, Then Placebo |
|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 3/15 | 0/15 | 1/6 | 0/8 | 0/15 | 1/15 |
| PyrexiaGeneral disorders | 0/15 | 0/15 | 0/6 | 0/8 | 2/15 | 3/15 |
| Upper respiratory tract infectionInfections and infestations | 1/15 | 3/15 | 0/6 | 0/8 | 0/15 | 2/15 |
| ConstipationGastrointestinal disorders | 0/15 | 0/15 | 1/6 | 0/8 | 0/15 | 0/15 |
| NasopharyngitisInfections and infestations | 2/15 | 1/15 | 1/6 | 0/8 | 0/15 | 0/15 |
| Abdominal painGastrointestinal disorders | 1/15 | 2/15 | 0/6 | 0/8 | 2/15 | 1/15 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 1/15 | 0/6 | 0/8 | 2/15 | 2/15 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/15 | 0/15 | 0/6 | 0/8 | 2/15 | 1/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/15 | 0/15 | 0/6 | 1/8 | 2/15 | 0/15 |
| OtorrhoeaEar and labyrinth disorders | 0/15 | 0/15 | 0/6 | 1/8 | 0/15 | 0/15 |
| Age Continuous(years) | Low Dose | Medium Dose | High Dose | Total |
|---|---|---|---|---|
| Mean | 3.4 ± 1.28 | 3.2 ± 1.48 | 3.3 ± 1.53 | 3.3 ± 1.41 |
| Sex: Female, Male(Participants) | Low Dose | Medium Dose | High Dose | Total |
|---|---|---|---|---|
| Female | 13 | 4 | 9 | 26 |
| Male | 17 | 10 | 21 | 48 |
The record gives a start of Mar 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years 4 months after primary completion. A results delay was requested in Dec 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valsartan